secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2026-05-13T11:30:50+00:00
Accession:  0001493152-26-022610
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Q1 net product revenue $8.7M; three ZEVASKYN patients treated; in-licenses PSMA T-cell therapy
--------------------------------------------------------------------------------

- Net product revenue of $8.7M from ZEVASKYN, up from $2.4M in Q4 2025; net loss $17.1M ($0.30/sh).
- Cash and investments $168.3M as of March 31, 2026, down from $191.4M at year-end 2025.
- Three patients treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites including CHOP and Columbia.
- In-licensed ABO-701 (PSMA-SIR-T) engineered T-cell therapy for prostate cancer; IND expected H2 2027.
- Deprioritized in-house ophthalmology programs to focus on ZEVASKYN and ABO-701.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer